ALB and neutropenia: Albumin-bound NPs translated PTX into the commercial cancer drug Abraxane, for which the phase III data indicated that albumin allowed a 1.5-fold increase in MTD of Abraxane than that of free PTX; however, when the dose was beyond MTD, 25% of patients notably suffered from neutropenia [57].